Inhibikase Therapeutics, Inc. (IKT) Interest Expense USD 2020 - 2022

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Interest Expense history and growth rate from 2020 to 2022.
  • Inhibikase Therapeutics, Inc. Interest Expense for the quarter ending September 30, 2022 was $0.000, a 100% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Interest Expense for 2021 was $19.9 K, a 32.2% decline from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 $0 -$157 -100% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q1 2022 $8.13 K $5.00* -$11.8 K -100% Jan 1, 2022 Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $19.9 K $158 -$6.98 K -97.8% Oct 1, 2021 Dec 31, 2021 10-K 2022-03-31
Q3 2021 $26.9 K $157 -$6.73 K -97.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $33.6 K $7.81 K -$137 -1.72% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $33.8 K $11.8 K +$4.37 K +58.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $29.4 K $7.14 K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $6.89 K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $7.95 K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $7.43 K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.